Two years of tamoxifen or no adjuvant systemic therapy for patients with high-risk breast cancer: long-term follow-up of the Copenhagen breast cancer trial

References

• Jensen EV, Block GE, Smith S, et al. Estrogen receptors and breast cancer response to adrenalectomy. Natl Cancer Inst Monogr. 1971;34:55–70.
   PubMedGoogle Scholar
• Cole MP, Jones CT, Todd ID. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer. 1971;25:270–275.
   PubMed Web of Science ®Google Scholar
• Hubay CA, Pearson OH, Marshall JS, et al. Adjuvant chemotherapy, antiestrogen therapy and immunotherapy for stage II breast cancer: 45-month follow-up of a prospective, randomized clinical trial. Cancer. 1980;46(12 Suppl):2805–2808.
   Web of Science ®Google Scholar
• Fisher B, Redmond C, Brown A, et al. Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med. 1981;305:1–6.
   PubMed Web of Science ®Google Scholar
• Rose C, Thorpe SM, Mouridsen HT, et al. Antiestrogen treatment of postmenopausal women with primary high risk breast cancer. Breast Cancer Res Tr. 1983;3:77–84.
   PubMed Web of Science ®Google Scholar
• Baum M, Brinkley DM, Dossett JA, et al. Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer. Lancet. 1983;2:450.
   PubMed Web of Science ®Google Scholar
• Mouridsen HT, Palshof T. Adjuvant systemic therapy in breast cancer; a review. Eur J Cancer Clin Oncol. 1983;19:1753–1770.
   PubMedGoogle Scholar
• Consensus conference. Adjuvant chemotherapy for breast cancer. JAMA. 1985;254:3461–3463.
   Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med. 1988;319:1681–1692.
   PubMed Web of Science ®Google Scholar
• Stewart HJ, Prescott RJ, Forrest AP. Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst. 2001;93:456–462.
   PubMed Web of Science ®Google Scholar
• Rutqvist LE, Johansson H. Stockholm Breast Cancer Study Group. Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer. Acta Oncol. 2007;46:133–145.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771–784.
   PubMed Web of Science ®Google Scholar
• Knoop AS, Laenkholm AV, Jensen MB, Danish Breast Cancer Cooperative Group, et al. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial. Eur J Cancer. 2014;50:1412–1421.
   PubMed Web of Science ®Google Scholar
• Ekholm M, Bendahl PO, Fernö M, et al. Two years of adjuvant tamoxifen provides a survival benefit compared with no systemic treatment in premenopausal patients with primary breast cancer: long-term follow-up (>25 years) of the Phase III SBII:2pre trial. JCO. 2016;34:2232–2238.
   PubMed Web of Science ®Google Scholar
• Palshof T, Mouridsen HT, Daehnfeldt JL. Adjuvant endocrine therapy of primary operable breast cancer. Report on the Copenhagen breast cancer trial. In: Mouridsen H T and Palshof T, editors. Breast cancer–experimental and clinical aspects. Oxford (UK): Pergamon Press; 1979. p. 183–8.
   Google Scholar
• Kaae S, Johansen H. Simple mastectomy plus postoperative irradiation by the method of McWhirter for mammary carcinoma. Ann Surg. 1969;170:895–899.
   PubMed Web of Science ®Google Scholar
• Thorpe SM, Poulsen HS, Pedersen KO, et al. Quality control of receptor analyses of breast cancer tissue in Denmark. Acta Oncol. 1988;27:621–625.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Pedersen L, Sørensen HT. The Danish civil registration system as a tool in epidemiology. Eur J Epidemiol. 2014;29:541–549.
   PubMed Web of Science ®Google Scholar
• Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17:343–346.
   PubMedGoogle Scholar
• EBCTCG (Early Breast Cancer Trialists’ Collaborative Group), McGale P, Taylor C, Correa C, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383:2127–2135.
   PubMed Web of Science ®Google Scholar
• BIG 1-98 Collaborative Group, Mouridsen H, Giobbie-Hurder A, Goldhirsch A, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009;361:766–776.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386:1341–1352.
   PubMed Web of Science ®Google Scholar
• Horwitz KB, McGuire WL, Pearson OH, et al. Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science. 1975;189:726–727.
   PubMed Web of Science ®Google Scholar
• EORTC Breast Cancer Co-operative Group. Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second E.O.R.T.C. Workshop, held on 16-17 March, 1979, in the Netherlands cancer institute. Eur J Cancer. 1980;16:1513–1515.
   PubMed Web of Science ®Google Scholar
• Koenders A, Thorpe SM. Standardization of steroid receptor assays in human breast cancer–I. Reproducibility of estradiol and progesterone receptor assays. Eur J Cancer Clin Oncol. 1983;19:1221–1229.
   PubMedGoogle Scholar
• Dignam JJ, Dukic V, Anderson SJ, et al. Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer. Breast Cancer Res Treat. 2009;116:595–602.
   PubMed Web of Science ®Google Scholar